EP3692050A4 - A new crystalline form of anhydrous 17- - Google Patents

A new crystalline form of anhydrous 17- Download PDF

Info

Publication number
EP3692050A4
EP3692050A4 EP18864585.7A EP18864585A EP3692050A4 EP 3692050 A4 EP3692050 A4 EP 3692050A4 EP 18864585 A EP18864585 A EP 18864585A EP 3692050 A4 EP3692050 A4 EP 3692050A4
Authority
EP
European Patent Office
Prior art keywords
anhydrous
crystalline form
new crystalline
new
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18864585.7A
Other languages
German (de)
French (fr)
Other versions
EP3692050A1 (en
Inventor
Lukasz SZELESZCZUK
Ewa JURCZAK
Dariusz Maciej PISKLAK
Monika ZIELINSKA-PISKLAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warszawski Uniwersytet Medyczny
Original Assignee
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny filed Critical Warszawski Uniwersytet Medyczny
Publication of EP3692050A1 publication Critical patent/EP3692050A1/en
Publication of EP3692050A4 publication Critical patent/EP3692050A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EP18864585.7A 2017-10-03 2018-10-03 A new crystalline form of anhydrous 17- Pending EP3692050A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL423041A PL236889B1 (en) 2017-10-03 2017-10-03 New crystalline form of anhydrous 17-β-estradiol, method for obtaining it and pharmaceutical composition that contains new crystalline form of anhydrous 17-β-estradiol and its application
PCT/PL2018/050050 WO2019070139A1 (en) 2017-10-03 2018-10-03 A NEW CRYSTALLINE FORM OF ANHYDROUS 17-β-ESTRADIOL, A METHOD FOR ITS PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING A NEW CRYSTALLINE FORM OF ANHYDROUS 17-β-ESTRADIOL AND ITS APPLICATION

Publications (2)

Publication Number Publication Date
EP3692050A1 EP3692050A1 (en) 2020-08-12
EP3692050A4 true EP3692050A4 (en) 2021-06-16

Family

ID=65992083

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18864585.7A Pending EP3692050A4 (en) 2017-10-03 2018-10-03 A new crystalline form of anhydrous 17-

Country Status (3)

Country Link
EP (1) EP3692050A4 (en)
PL (1) PL236889B1 (en)
WO (1) WO2019070139A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997897A (en) * 1992-07-16 1999-12-07 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Process for the production of a transdermal therapeutic system comprising the active substance 17-β-estradiol (anhydrous)
US20020168395A1 (en) * 1998-02-25 2002-11-14 John-Claude Savoir Stable shaped particles of crystalline organic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827245A (en) * 1992-07-16 1998-10-27 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising the active subtance 17-β-Estradiol (Anhydrous)
US5928666A (en) * 1996-11-12 1999-07-27 Cygnus Inc. Crystalline form of estradiol and pharmaceutical formulations comprising same
EA005116B1 (en) * 2000-10-20 2004-10-28 Эли Лилли Энд Компани A NOVEL CRYSTALLINE FORM OF 6-HUDROXY-3-(4-[2-PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997897A (en) * 1992-07-16 1999-12-07 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Process for the production of a transdermal therapeutic system comprising the active substance 17-β-estradiol (anhydrous)
US20020168395A1 (en) * 1998-02-25 2002-11-14 John-Claude Savoir Stable shaped particles of crystalline organic compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KUHNERT-BRANDSTÄTTER UND H WINKLER M: "Thermoanalytische und IR-spektroskopische Untersuchungen an verschiedenen Kristallformen von Arzneistoffen aus der Östradiol- und Androstangruppe", SCIENTIA PHARMACEUTICA, OESTERREICHISCHE APOTHEKER-VERLAGSGESELLSCHAFT MBH, AUSTRIA, vol. 44, no. 3, 30 September 1976 (1976-09-30), pages 177 - 190, XP009527368, ISSN: 0036-8709 *
SALOLE E.G.: "The physicochemical properties of oestradiol", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 5, no. 7, 1 January 1987 (1987-01-01), AMSTERDAM, NL, pages 635 - 648, XP055802013, ISSN: 0731-7085, DOI: 10.1016/0731-7085(87)80076-6 *
See also references of WO2019070139A1 *
VARIANKAVAL N E ET AL: "Characterization of crystal forms of @b-estradiol - thermal analysis, Raman microscopy, X-ray analysis and solid-state NMR", JOURNAL OF CRYSTAL GROWTH, ELSEVIER, AMSTERDAM, NL, vol. 217, no. 3, 1 August 2000 (2000-08-01), pages 320 - 331, XP004213544, ISSN: 0022-0248, DOI: 10.1016/S0022-0248(00)00442-5 *

Also Published As

Publication number Publication date
PL423041A1 (en) 2019-04-08
PL236889B1 (en) 2021-02-22
WO2019070139A1 (en) 2019-04-11
EP3692050A1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
IL273730A (en) Crystalline forms
EP3136857A4 (en) Crystalline form of baricitinib
EP3541807A4 (en) Crystalline forms of a magl inhibitor
EP3183803A4 (en) Tuning of a kinematic relationship between members
EP3183804A4 (en) Tuning of a kinematic relationship between members
EP3619208C0 (en) Crystalline forms of a jak inhibitor compound
EP3290406A4 (en) Novel crystal of uracil compound
EP3129838A4 (en) Time-synchronizing a group of nodes
EP3390422A4 (en) Crystalline forms of lnt
EP3684358A4 (en) New crystalline polymorph of ponesimod
EP3337485A4 (en) Crystalline forms of ibrutinib
GB201522771D0 (en) Crystalline form of a phosphate derivative
EP3250562A4 (en) Crystalline forms of c21h22ci2n4o2
EP3310352A4 (en) Crystalline compounds
PL3532457T3 (en) Crystalline forms of hydroxynorketamine
EP3285792A4 (en) Clec11a is a bone growth agent
EP3113773A4 (en) Crystalline forms of grapiprant
EP3207034A4 (en) Anhydrous crystalline form of s-equol
EP3247399A4 (en) Crystalline forms of efinaconazole
HK1252842A1 (en) Crystalline forms of thienopyrimidine compound
IL270961A (en) Crystalline form of n-butyldeoxygalactonojirimycin
EP3793980A4 (en) Crystalline form of s-apomorphine
IL269792B (en) Crystalline forms of (s)-afoxolaner
IL269073A (en) Crystalline forms of obeticholic acid
HK1246786A1 (en) Crystalline forms of a pyrrolopyridine compound

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200504

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210518

RIC1 Information provided on ipc code assigned before grant

Ipc: C07J 1/00 20060101AFI20210511BHEP

Ipc: A61K 31/565 20060101ALI20210511BHEP

Ipc: A61P 5/30 20060101ALI20210511BHEP

Ipc: A61P 15/18 20060101ALI20210511BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240328